Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
J Eur Acad Dermatol Venereol
; 36(10): 1774-1783, 2022 Oct.
Article
in En
| MEDLINE
| ID: mdl-35460287
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Metabolic Syndrome
/
Antibodies, Monoclonal, Humanized
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
J Eur Acad Dermatol Venereol
Journal subject:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: